Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 6Hepatitis B 5Recurrence 3Lymphoma 3Neoplasms 2Virus Diseases 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Non-Hodgkin 1Liver Neoplasms 1Liver Failure, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Glioma 1Fibrosis 1Extensive Stage Lung Small Cell Carcinoma 1Colorectal Neoplasms 1

Interventions

Fluorouracil 498Bevacizumab 476Oxaliplatin 450Leucovorin 442Irinotecan 408Cetuximab 318Capecitabine 317pembrolizumab 142Folfox protocol 128Panitumumab 117regorafenib 105Colonoscopy 88Nivolumab 82IFL protocol 81Drug Therapy 77trifluridine tipiracil drug combination 73Radiotherapy 66HMPL-013 65Blood Specimen Collection 52Gemcitabine 49Specimen Handling 47Standard of Care 45Neoadjuvant Therapy 45Magnetic Resonance Spectroscopy 44Biopsy 44Chemotherapy, Adjuvant 41Trifluridine 40atezolizumab 39Cyclophosphamide 39Surveys and Questionnaires 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colorectal Neoplasms × Lamivudine × Clear all
NCT03144804 2024-06-06

A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer

Massachusetts General Hospital

Phase 2 Completed
36 enrolled 11 charts
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡